Health News Releases

March 02, 2022 10:15

FDA Accepts Alvotech’s BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira®

Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S.

March 02, 2022 10:05

Glucophage® Is the First Oral Diabetes Treatment Approved in Europe for Use During Pregnancy

Merck, a leading science and technology company, today announced in a European worksharing procedure (WSP) an extension to the label for metformin products in the EU - Glucophage® (metformin hydrochlo

February 28, 2022 15:40

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220227005069/en/ Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

February 28, 2022 09:49

Oncocross Begins Phase I Clinical Trial of AI-Developed Drug for Sarcopenia

Oncocross, an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for ‘OC514’ targeting muscular diseases including sarcopenia. Oncocross obtained Austral

February 25, 2022 11:00

GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer’s Disease

GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to treat and prevent neurological diseases, and the Wyss Center, a non-profit organization dedicated

February 25, 2022 10:34

GI Innovation and Cellkey to Develop Next-generation Innovative Immuno-oncology through Biomarker Joint Research

GI Innovation, an innovative new drug development company, announced that it signed a biomarker joint research MoU with CellKey, a Glycoprotein biomarker development company, to develop next-generatio

February 25, 2022 09:25

New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression

Merck, a leading science and technology company, today announced new real-world data from the MSBase Registry demonstrating MAVENCLAD® (cladribine tablets) had more favourable relapse outcomes and lon

February 24, 2022 10:00

Protein Hydrolysate Ingredients Market is expected to reach USD 1.0 Billion by 2031, growing at a CAGR of 7.30% during 2021- 2031: Future Market Insights

The global sales of protein hydrolysate ingredients are expected to grow by 6.80% in 2021, reaching 33,268 MT in terms of volume. Future Market Insights (FMI) forecasts that the protein hydrolysate in

February 23, 2022 16:40

rf IDEAS and Key Partners to Spotlight Healthcare IAM Solutions at HIMSS22

rf IDEAS, a global leader in the design and manufacture of credential readers for authentication and logical access, will be on site at the HIMSS22 Conference in Orlando, Florida (Booth #1313) with ke

February 23, 2022 11:43

Taro to Acquire Alchemee From Galderma

Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from G

February 23, 2022 10:50

Kaneka Eurogentec Announces the Successful Production of 25g of mRNA in One Batch

Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization (CDMO), announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for

February 23, 2022 10:00

Laboratory Information Systems Market is slated to increase at a CAGR of 10.2% to reach a valuation of USD 4.2 Billion by 2030: Future Market Insights

Global laboratory information system (LIS) market revenues are set to grow at 10.2% CAGR through 2030, according to an updated edition by Future Market Insights (FMI). The 2022-2030 version of the rep

February 22, 2022 16:00

Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”) today announced the results from an analysis of a total of 37 individuals enrolled in its Evaluation and Assessment o

February 22, 2022 15:54

Advanced Wound Management Market is projected to grow at a steady pace, exceeding a market valuation of USD 6.5 Billion between 2021 and 2031: Future Market Insights

Growing investments in the healthcare sector, coupled with innovations in advanced wound management products are anticipated to positively shape demand in the upcoming years. With an increasing inc

February 21, 2022 11:55

European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

Merck, a leading science and technology company, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients

February 21, 2022 11:30

Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

Merck, a leading science and technology company, today announced the results of an exploratory analysis from the Phase III JAVELIN Bladder 100 trial with 19 additional months of follow-up data from th

February 21, 2022 10:35

Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study[1,2]

Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission[*] was observed in 65% of patients in both cohorts who were evaluated

February 18, 2022 16:28

Karen L. Ling joins Galderma’s Advisory Committee

Galderma, the world’s largest independent dermatology company, announced today that Karen L. Ling will join its Advisory Committee, effective March 1, 2022. Karen Ling has a tremendous track record

February 18, 2022 09:10

NEC OncoImmunity Publishes a Unique HLA Typing Technology That Discovers New HLA Alleles, and Tumor Specific HLA Alleles

NEC OncoImmunity AS (NOI) today announced a publication that describes a novel approach to type new HLA alleles and characterize the HLA of tumors to guide personalized cancer immunotherapy. The co

February 17, 2022 15:20

Vifor Pharma reports sustained growth in 2021

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group reported a solid performance in 2021 and an increase in profitability, supported by a strong recovery in Ferinject®

February 17, 2022 11:40

Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam

Organon (NYSE: OGN) today announced that it has acquired the rights from Bayer AG to Marvelon® and Mercilon®, combined oral hormonal daily contraceptive pills, in the People’s Republic of China, inclu

February 17, 2022 10:21

Capsa Healthcare Announces the Acquisition of Humanscale Healthcare

Capsa Healthcare, a leading innovator in healthcare delivery solutions for hospitals, long-term care, and retail pharmacy providers, announced the acquisition of Humanscale Healthcare, a designer and

February 16, 2022 11:46

Medidata Opens Access to its Patient Insights Program, Enabling Sponsors and CROs to Leverage Proprietary Patient Centricity by Design Process for Clinical Trials

Medidata, a Dassault Systèmes company, today announced it is allowing sponsors, CROs (contract research organizations), and sites to leverage its proprietary Patient Centricity by Design process for c

February 16, 2022 11:43

BreastScreen Victoria Switches to Rimini Street Support for its Oracle Database Software, Unlocks Resources to Meet Increasing Service Demand

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partn

February 16, 2022 10:03

German Federal Court of Justice Upholds AOP‘s License Rights in Ropeginterferon and PEC’s Liability for Damages.

Since 2017, PharmaEssentia had repeatedly attempted to terminate the agreement with AOP concerning BESREMi® (Ropeginterferon alfa-2b). In October 2020, after two and a half years of arbitral proceedin

News by Region

News by Industry